arrow
I

Isabel Virchow

university of duisburg essen
H指数:9
被引数:313

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

在重度预处理的转移性结直肠癌中,比较雷莫芦单抗联合TAS102(三氟尿苷/替吡拉塞)与TAS102单药治疗的随机III期试验:德国AIO(AIO-KRK-0316)的RAMTAS/IKF643试验

2024-09-010
PRE
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies

未知原发癌的综合生物标志物诊断,以确定符合精确医疗治疗条件的患者

2024-03-012
OA
SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary

在初次诊断检查时,18F-FDG PET/CT中SUVmax高于20与未知原发癌患者的良好生存率相关

2023-06-155
OA
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial

每两周西妥昔单抗联合FOLFOX6作为RAS野生型转移性结直肠癌患者的一线治疗: CEBIFOX试验

2020-12-017
PREAI
Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO
2020-09-012
OAAI
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
2018-07-0166
PREAI
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
2017-03-0128
OAAI